Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects with Solid Tumors
jRCT2080221644Phase 1
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-833923 in Nonhematologic neoplasms (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability of BMS-833923 (XL139) and Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D).
02
Drugs
BMS-833923
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080221644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221644.